HGFAC and medulloblastoma: Remarkably, none of the seven LDE225-treated FSmoM2;hGFAP-cre medulloblastomas had acquired mutations in the SHH pathway (Fig. 1E; Supplementary Fig. S1I; Supplementary Table S5).